» Articles » PMID: 35415045

High Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio and Low Lymphocyte Levels Are Correlated With Worse Pathological Complete Response Rates

Overview
Journal Cureus
Date 2022 Apr 13
PMID 35415045
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the effect of hemogram parameters on predicting pathological complete response (pCR) in locally advanced rectal cancer.

Methodology: A total of 227 patients with rectal cancer treated with neoadjuvant concurrent chemoradiotherapy (CRT) were retrospectively analyzed. All patients were divided into two subgroups as high or low hemogram parameters according to the cut-off value obtained using the receiver operating characteristic (ROC) curve.

Results: In patients with low neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) levels, pCR rate was statistically significantly higher than the group with high NLR and PLR levels (for NLR: 39.77% vs. 5.34%; p<0.001, for PLR: 32.38% vs 7.01%; p<0.001 respectively). In addition, the pCR rate was significantly better in patients with high lymphocyte levels compared to the group with low lymphocyte levels (33.33% vs. 7.5%; p<0.001, respectively). According to the multivariate logistic regression analysis result, NLR and PLR levels were considered as independent predictors to predict pathological complete response [p<0.001, HR: 0.128 (95% CI=0.051 - 0.322) for NLR; p=0.017, HR: 0.332 (95% CI=0.134 - 0.821) for PLR, respectively].

Conclusion: Our study showed that high NLR, PLR, and low lymphocyte levels were correlated with worse pCR rates. In addition to that, NLR and PLR emerged as independent predictive markers.

Citing Articles

Evaluation of Predictive and Prognostic Importance of Lung Immune Prognostic Index in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.

Arikan R, Alkis H, Isik S, Yasar A, Celebi A, Majidova N Cureus. 2023; 15(6):e40548.

PMID: 37465788 PMC: 10350655. DOI: 10.7759/cureus.40548.


Is It Really Gone? Assessing Response to Neoadjuvant Therapy in Rectal Cancer.

Kimura C, Crowder S, Kin C J Gastrointest Cancer. 2022; 54(3):703-711.

PMID: 36417142 DOI: 10.1007/s12029-022-00889-x.


Prognostic value of the modified systemic inflammation score in non-small-cell lung cancer with brain metastasis.

Wang F, Chen L, Wang Z, Xu Q, Huang H, Wang H Cancer Cell Int. 2022; 22(1):320.

PMID: 36242047 PMC: 9563131. DOI: 10.1186/s12935-022-02704-w.

References
1.
Guillem J, Chessin D, Cohen A, Shia J, Mazumdar M, Enker W . Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005; 241(5):829-36. PMC: 1357138. DOI: 10.1097/01.sla.0000161980.46459.96. View

2.
Kim S, Chang H, Kim D, Park J, Baek J, Kim S . What Is the Ideal Tumor Regression Grading System in Rectal Cancer Patients after Preoperative Chemoradiotherapy?. Cancer Res Treat. 2015; 48(3):998-1009. PMC: 4946373. DOI: 10.4143/crt.2015.254. View

3.
Li A, He K, Guo D, Liu C, Wang D, Mu X . Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer. Future Oncol. 2019; 15(28):3233-3242. DOI: 10.2217/fon-2019-0389. View

4.
Eraslan E, Adas Y, Yildiz F, Ilhan Gulesen A, Karacin C, Yalcintas Arslan U . Systemic Immune-inflammation Index (SII) Predicts Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. J Coll Physicians Surg Pak. 2021; 31(4):399-404. DOI: 10.29271/jcpsp.2021.04.399. View

5.
Ramsay G, Ritchie D, MacKay C, Parnaby C, Murray G, Samuel L . Can Haematology Blood Tests at Time of Diagnosis Predict Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer?. Dig Surg. 2018; 36(6):495-501. DOI: 10.1159/000493433. View